Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Colombia Médica
versión On-line ISSN 1657-9534
Resumen
OSPINA, Fabio E et al. Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report. Colomb. Med. [online]. 2017, vol.48, n.2, pp.88-93. ISSN 1657-9534.
Case description:
Five-year-old female patient with hereditary hemorrhagic telangiectasia.
Clinical Findings:
Deterioration of cardiopulmonary function with higher oxygen requirements secondary to pulmonary arteriovenous shunts, epistaxis.
Treatment and Outcome:
The patient was treated with the monoclonal antibody bevacizumab, which inhibits the vascular endothelial growth factor, with good clinical outcome.
Clinical Relevance:
Hereditary hemorrhagic telangiectasia is an autosomal dominant disorder characterized by arteriovenous malformations in different organs, making its clinical presentations varied. Systemic therapeutic options for a generalized disease are limited. The monoclonal antibody bevacizumab, seems to be a good option in this disorder. Although reported as successful in adult population, its use in pediatric population has not yet been reported. Here we report the use of bevacizumab in a 5-year-old female patient with hereditary hemorrhagic telangiectasia, showing clinical benefits and good outcome.
Palabras clave : Telangiectasia Hereditary Hemorrhagic; Bevacizumab; Osler-Rendu-Weber Disease; Pediatrics.